Controlled Release of Bevacizumab Through Nanospheres for Extended Treatment of Age-Related Macular Degeneration

Bevacizumab (Avastin(®)) has been used by ophthalmologists in many countries as an off-label drug for the treatment of wet age-related macular degeneration (AMD). Due to its short half-life necessitating frequent intravitreal injection, a method for sustained delivery is in need. We demonstrated tha...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Fengfu, Hurley, Bernard, Liu, Yun, Leonard, Brian, Griffith, May
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Bentham Open 2012
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3394187/
https://www.ncbi.nlm.nih.gov/pubmed/22798970
http://dx.doi.org/10.2174/1874364101206010054
_version_ 1782237826379677696
author Li, Fengfu
Hurley, Bernard
Liu, Yun
Leonard, Brian
Griffith, May
author_facet Li, Fengfu
Hurley, Bernard
Liu, Yun
Leonard, Brian
Griffith, May
author_sort Li, Fengfu
collection PubMed
description Bevacizumab (Avastin(®)) has been used by ophthalmologists in many countries as an off-label drug for the treatment of wet age-related macular degeneration (AMD). Due to its short half-life necessitating frequent intravitreal injection, a method for sustained delivery is in need. We demonstrated that bevacizumab could be released in a sustained fashion over 90 days from nano- and microspheres fabricated from poly(DL-lactide-co-glycolide) and poly(ethylene glycol)-b-poly(D,L-lactic acid), respectively. The drug release rate could be adjusted by alteration of the drug/polymer ratio. The use of such nano- and microspheres as bevacizumab delivery vehicles may improve the treatment of wet AMD.
format Online
Article
Text
id pubmed-3394187
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Bentham Open
record_format MEDLINE/PubMed
spelling pubmed-33941872012-07-13 Controlled Release of Bevacizumab Through Nanospheres for Extended Treatment of Age-Related Macular Degeneration Li, Fengfu Hurley, Bernard Liu, Yun Leonard, Brian Griffith, May Open Ophthalmol J Article Bevacizumab (Avastin(®)) has been used by ophthalmologists in many countries as an off-label drug for the treatment of wet age-related macular degeneration (AMD). Due to its short half-life necessitating frequent intravitreal injection, a method for sustained delivery is in need. We demonstrated that bevacizumab could be released in a sustained fashion over 90 days from nano- and microspheres fabricated from poly(DL-lactide-co-glycolide) and poly(ethylene glycol)-b-poly(D,L-lactic acid), respectively. The drug release rate could be adjusted by alteration of the drug/polymer ratio. The use of such nano- and microspheres as bevacizumab delivery vehicles may improve the treatment of wet AMD. Bentham Open 2012-06-25 /pmc/articles/PMC3394187/ /pubmed/22798970 http://dx.doi.org/10.2174/1874364101206010054 Text en © Li et al.; Licensee Bentham Open. http://creativecommons.org/licenses/by-nc/3.0/ This is an open access article licensed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.
spellingShingle Article
Li, Fengfu
Hurley, Bernard
Liu, Yun
Leonard, Brian
Griffith, May
Controlled Release of Bevacizumab Through Nanospheres for Extended Treatment of Age-Related Macular Degeneration
title Controlled Release of Bevacizumab Through Nanospheres for Extended Treatment of Age-Related Macular Degeneration
title_full Controlled Release of Bevacizumab Through Nanospheres for Extended Treatment of Age-Related Macular Degeneration
title_fullStr Controlled Release of Bevacizumab Through Nanospheres for Extended Treatment of Age-Related Macular Degeneration
title_full_unstemmed Controlled Release of Bevacizumab Through Nanospheres for Extended Treatment of Age-Related Macular Degeneration
title_short Controlled Release of Bevacizumab Through Nanospheres for Extended Treatment of Age-Related Macular Degeneration
title_sort controlled release of bevacizumab through nanospheres for extended treatment of age-related macular degeneration
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3394187/
https://www.ncbi.nlm.nih.gov/pubmed/22798970
http://dx.doi.org/10.2174/1874364101206010054
work_keys_str_mv AT lifengfu controlledreleaseofbevacizumabthroughnanospheresforextendedtreatmentofagerelatedmaculardegeneration
AT hurleybernard controlledreleaseofbevacizumabthroughnanospheresforextendedtreatmentofagerelatedmaculardegeneration
AT liuyun controlledreleaseofbevacizumabthroughnanospheresforextendedtreatmentofagerelatedmaculardegeneration
AT leonardbrian controlledreleaseofbevacizumabthroughnanospheresforextendedtreatmentofagerelatedmaculardegeneration
AT griffithmay controlledreleaseofbevacizumabthroughnanospheresforextendedtreatmentofagerelatedmaculardegeneration

Ejemplares similares